Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

7.37
-0.5900-7.41%
Post-market: 7.760.3900+5.29%19:42 EDT
Volume:1.59M
Turnover:11.82M
Market Cap:1.01B
PE:-1.92
High:7.84
Open:7.69
Low:7.25
Close:7.96
Loading ...

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Business Wire
·
25 Nov 2024

TD Cowen Keeps Their Buy Rating on Vir Biotechnology (VIR)

TIPRANKS
·
20 Nov 2024

Vir Biotechnology Price Target Maintained With a $19.00/Share by Needham

Dow Jones
·
20 Nov 2024

U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart

Reuters
·
20 Nov 2024

Vir Biotechnology announces results from SOLSTICE trial

TIPRANKS
·
19 Nov 2024

BRIEF-Vir Biotechnology Says Tobevibart And Elebsiran Achieve 100% Virologic Suppression At Week 24

Reuters
·
19 Nov 2024

Vir Biotechnology Inc - Ema Issues Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran

THOMSON REUTERS
·
19 Nov 2024

Vir Biotechnology Inc - Phase 3 Eclipse Program to Begin in First Half of 2025

THOMSON REUTERS
·
19 Nov 2024

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

THOMSON REUTERS
·
19 Nov 2024

Vir Biotechnology Inc - Tobevibart and Elebsiran Achieve 100% Virologic Suppression at Week 24

THOMSON REUTERS
·
19 Nov 2024

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Business Wire
·
19 Nov 2024

Vir Biotechnology Prospective Treatment for Hepatitis Delta Gets EU Advisory Committee Recommendation

MT Newswires Live
·
19 Nov 2024

Vir Biotechnology gets positive opinion on orphan drug designation for Tobevibar

TIPRANKS
·
19 Nov 2024

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta From European Medicines Agency

THOMSON REUTERS
·
19 Nov 2024

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Business Wire
·
19 Nov 2024

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?

Benzinga
·
16 Nov 2024